Anti-trem2 antibody and uses thereof
AssigneeVigil Neuroscience, Inc.
InventorsSpyridon PAPAPETROPOULOS, Evan Andrew THACKABERRY, David K. STILES, Andrew J. MARSH, Ryan O'MARA
Life of this patent
Estimating the term…
Abstract
The present invention provides anti-TREM2 antibodies, formulations thereof, and methods of use thereof.
Claims24
A method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, comprising administering to the patient in need thereof an anti-TREM2 antibody at a dose of about 1-100 mg/kg, wherein the anti-TREM2 antibody comprises:
- (a) a light chain variable region comprising a CDRL1 having an amino acid sequence according to SEQ ID NO:
- 2;
- a CDRL2 having an amino acid sequence according to SEQ ID NO:
- 3;
- and a CDRL3 having an amino acid sequence according to SEQ ID NO:
- 4, and a heavy chain variable region comprising a CDRH1 having an amino acid sequence according to SEQ ID NO:
- 6;
- a CDRH2 having an amino acid sequence according to SEQ ID NO:
- 7;
- and a CDRH3 having an amino acid sequence according to SEQ ID NO:
- 8;
- or
- (b) a light chain variable region having an amino acid sequence according to SEQ ID NO:
- 1, and a heavy chain variable region having an amino acid sequence according to SEQ ID NO:
- 5.
A liquid formulation comprising anti-TREM2 antibody VGL101 at a concentration of about 140 mg/mL, and a pharmaceutically acceptable excipient and/or carrier.
A liquid formulation at about pH 5.2, comprising:
- anti-TREM2 antibody VGL101 at a concentration of about 140 mg/mL;
- sodium acetate at a concentration of about 15 mM;
- sucrose at a concentration of about 9% (w/v) of total liquid formulation volume;
- and
- Polysorbate 80 at a concentration of about 0.01% (w/v) of total liquid formulation volume.
A method of reducing a level of sTREM2 or sCSF1R in a subject, comprising administering anti-TREM2 antibody VGL101 to the subject at a dose of about 1-100 mg/kg.
A method of engaging or agonizing TREM2 in a subject, comprising administering anti-TREM2 antibody VGL101 to the subject at a dose of about 1-100 mg/kg.
Dependencies are inferred from the claim text.